Immunohistochemistry was performed on paraffin-embedded adenocarcinoma of human breast tissue. To expose target proteins, 10mM citric buffer, pH6.0, 100°C for 10min was used. Following antigen retrieval, tissues were probed with a SERPINB2 monoclonal antibody (Product # MA5-25777).

Product Image Gallery

Product Details

MA5-25777

Applications

Tested Dilution

Publications

Western Blot (WB)

1:2,000

Immunohistochemistry (Paraffin) (IHC (P))

1:150

Flow Cytometry (Flow)

1:100

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

OTI1F6

Immunogen

Full length human recombinant protein of SERPINB2 produced in HEK293T cell

View immunogen

Conjugate

Unconjugated

Form

Liquid

Concentration

0.82 mg/mL

Purification

Affinity Chromatography

Storage buffer

PBS, pH 7.3, with 1% BSA, 50% glycerol

Contains

0.02% sodium azide

Storage conditions

-20°C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

AB_2725324

Target Information

PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa, nonglycosylated, intracellular protein, which can be induced to be secreted as 60 kDa glycoprotein. The glycosylated and unglycosylated forms of PAI-2 are equally effective as inhibitors of urokinase-type plasminogen activator (uPA), the only established physiological target of this serpin. PAI-2 has a unique ability to form dormant polymers spontaneously and reversibly under physiological conditions. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular, dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy, and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/ml), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?

Let us know so we can reference it here.

Cite this product

Bioinformatics

Protein Aliases: Monocyte Arg-serpin; PAI-2; Placental plasminogen activator inhibitor; Plasminogen activator inhibitor 2; plasminogen activator inhibitor, type II (arginine-serpin); serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2; Serpin B2; serpin peptidase inhibitor, clade B (ovalbumin), member 2; Urokinase inhibitor

Gene Aliases: HsT1201; PAI; PAI-2; PAI2; PLANH2; SERPINB2

UniProt ID: (Human) P05120

Entrez Gene ID: (Human) 5055

Function(s)

Process(es)

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

SERPINB2 Monoclonal Antibody (OTI1F6)

SERPINB2 Antibody (MA5-25777) in IHC (P)